Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Gene therapy such as oblimersen may make tumor cells more sensitive to chemotherapy drugs. Combining irinotecan and oblimersen may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining oblimersen and irinotecan in treating patients who have metastatic or recurrent colorectal cancer.

【理论依据】化疗（chemotherapy）药物可通过多种途径阻止肿瘤细胞分裂，使其停止增殖或死亡。诸如奥比姆森（oblimersen）这类基因治疗（gene therapy）手段，可增强肿瘤细胞对化疗药物的敏感性。联合使用伊立替康（irinotecan）与奥比姆森，或可杀伤更多肿瘤细胞。
【试验目的】开展I/II期临床试验，评估奥比姆森联合伊立替康治疗转移性或复发性结直肠癌患者的疗效。